[go: up one dir, main page]

WO1999026927A3 - Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central - Google Patents

Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central Download PDF

Info

Publication number
WO1999026927A3
WO1999026927A3 PCT/US1998/024833 US9824833W WO9926927A3 WO 1999026927 A3 WO1999026927 A3 WO 1999026927A3 US 9824833 W US9824833 W US 9824833W WO 9926927 A3 WO9926927 A3 WO 9926927A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabotropic glutamate
nervous system
central nervous
receptor antagonists
glutamate receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/024833
Other languages
English (en)
Other versions
WO1999026927A2 (fr
Inventor
Wagenen Bradford C Van
Scott T Moe
Daryl L Smith
Susan M Sheehan
Irina Shcherbakova
Richard Travato
Ruth Walton
Robert Barmore
Eric G Delmar
Thomas M Stormann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NPS Pharmaceuticals Inc filed Critical NPS Pharmaceuticals Inc
Priority to NZ505207A priority Critical patent/NZ505207A/en
Priority to EP98959535A priority patent/EP1037878A2/fr
Priority to IL13625098A priority patent/IL136250A0/xx
Priority to MXPA00004940A priority patent/MXPA00004940A/es
Priority to JP2000522085A priority patent/JP2001524468A/ja
Priority to AU15317/99A priority patent/AU771358B2/en
Priority to CA002311131A priority patent/CA2311131A1/fr
Publication of WO1999026927A2 publication Critical patent/WO1999026927A2/fr
Publication of WO1999026927A3 publication Critical patent/WO1999026927A3/fr
Priority to US09/573,347 priority patent/US6429207B1/en
Priority to IL136250A priority patent/IL136250A/en
Anticipated expiration legal-status Critical
Priority to US10/211,523 priority patent/US7053104B2/en
Priority to AU2004202776A priority patent/AU2004202776B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés et des compositions pharmaceutiques contenant lesdits composés, qui agissent comme antagonistes au niveau des récepteurs du glutamate métabotropes. Lesdits composés sont utiles pour le traitement de maladies et de troubles neurologiques. Des procédés de préparation desdits composés sont également décrits.
PCT/US1998/024833 1997-11-21 1998-11-20 Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central Ceased WO1999026927A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NZ505207A NZ505207A (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
EP98959535A EP1037878A2 (fr) 1997-11-21 1998-11-20 Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central
IL13625098A IL136250A0 (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonist compounds
MXPA00004940A MXPA00004940A (es) 1997-11-21 1998-11-20 Antagonistas de receptor de glutamato metabotropico para tratar enfermedades del sistema nervioso central.
JP2000522085A JP2001524468A (ja) 1997-11-21 1998-11-20 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
AU15317/99A AU771358B2 (en) 1997-11-21 1998-11-20 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
CA002311131A CA2311131A1 (fr) 1997-11-21 1998-11-20 Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central
US09/573,347 US6429207B1 (en) 1997-11-21 2000-05-19 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
IL136250A IL136250A (en) 1997-11-21 2000-05-21 Metabotropic glutamate receptor antagonist compounds
US10/211,523 US7053104B2 (en) 1997-11-21 2002-08-05 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
AU2004202776A AU2004202776B2 (en) 1997-11-21 2004-06-17 Metabotropic glutamate receptor antagonists for treating central nervous system diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6675897P 1997-11-21 1997-11-21
US60/066,758 1997-11-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/573,347 Continuation-In-Part US6429207B1 (en) 1997-11-21 2000-05-19 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases

Publications (2)

Publication Number Publication Date
WO1999026927A2 WO1999026927A2 (fr) 1999-06-03
WO1999026927A3 true WO1999026927A3 (fr) 1999-10-21

Family

ID=22071510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/024833 Ceased WO1999026927A2 (fr) 1997-11-21 1998-11-20 Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central

Country Status (9)

Country Link
EP (1) EP1037878A2 (fr)
JP (1) JP2001524468A (fr)
CN (2) CN1554649A (fr)
AU (2) AU771358B2 (fr)
CA (1) CA2311131A1 (fr)
IL (2) IL136250A0 (fr)
MX (1) MXPA00004940A (fr)
NZ (1) NZ505207A (fr)
WO (1) WO1999026927A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895050B2 (en) 2003-08-06 2014-11-25 Senomyx, Inc. Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044639A1 (fr) * 1998-03-03 1999-09-10 Yamanouchi Pharmaceutical Co., Ltd. Medicaments contre l'infarcissement du cerveau
GB9823845D0 (en) 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
GB9823847D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
WO2000073283A1 (fr) * 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Antagonistes du recepteur de glutamate metabotropique et leur utilisation pour le traitement de maladies du systeme nerveux central
WO2001010846A2 (fr) * 1999-08-05 2001-02-15 Igt Pharma Inc. Nouveaux composes de 1,4-benzodiazepine et derives de ces derniers
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ES2250177T3 (es) * 1999-08-19 2006-04-16 Nps Pharmaceuticals, Inc. Compuestos heteropoliciclicos y su uso como antagonistas de receptores de glutamato metabotropico.
EP1582519A3 (fr) * 1999-08-19 2005-12-21 Nps Pharmaceuticals, Inc. Composes heteropolycycliques et leur utilisation comme antagonistes des recepteurs glutamiques metabotropes
ATE250039T1 (de) * 1999-10-15 2003-10-15 Hoffmann La Roche Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
WO2001029012A2 (fr) 1999-10-15 2001-04-26 F. Hoffmann-La Roche Ag Derives de benzodiazepines
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
PL360677A1 (en) * 2000-10-02 2004-09-20 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
BR0212787A (pt) * 2001-09-24 2005-01-25 Elan Pharm Inc Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
JP4573533B2 (ja) * 2002-03-29 2010-11-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 放射能標識付きキノリンおよびキノリノン誘導体および代謝向性グルタメート受容体リガンドとしてのそれらの使用
CN100357283C (zh) * 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
PL375256A1 (en) * 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2004056744A1 (fr) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
AU2004209540A1 (en) * 2003-01-31 2004-08-19 Astrazeneca Ab Saturated quinoxaline derivatives and their use as metabotropic glutamate receptor ligands
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US7501416B2 (en) 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
CN101001836B (zh) 2004-05-07 2010-12-22 詹森药业有限公司 作为11-β羟基类固醇脱氢酶抑制剂的吡咯烷-2-酮和哌啶-2-酮衍生物
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
KR101197672B1 (ko) 2004-08-30 2012-11-07 얀센 파마슈티카 엔.브이. 11-베타 하이드록시스테로이드 데하이드로게나제저해제로서 트리사이클릭 락탐 유도체
WO2006024627A2 (fr) 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. Derives d'acetamides n-2 adamantanyl-2-phenoxy utilises en tant qu'inhibiteurs de la deshydrogenase 11-beta hydroxysteroide
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
AU2006210513C1 (en) 2005-02-04 2012-10-25 Senomyx, Inc. Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
WO2006097817A1 (fr) 2005-03-17 2006-09-21 Pfizer Japan Inc. Derives de n-(n-sulfonylaminomethyl)cyclopropanecarboxamide utilises pour traiter une douleur
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
TW200715993A (en) 2005-06-15 2007-05-01 Senomyx Inc Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers
CA2612338C (fr) 2005-06-17 2015-02-03 Apogee Biotechnology Corporation Inhibiteurs de la sphingosine kinase
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
WO2007021308A1 (fr) * 2005-08-12 2007-02-22 Astrazeneca Ab Isoindolones potentiateurs du récepteur glutamate métabotropique
WO2007037543A1 (fr) * 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. Dérivé de biarylamide
EP1957475A1 (fr) * 2005-10-21 2008-08-20 Merz Pharma GmbH & Co.KGaA Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate
WO2007071358A1 (fr) * 2005-12-20 2007-06-28 Novartis Ag Dérivés d'acide nicotinique en tant que modulateurs des récepteurs métabotropiques du glutamate
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
DK2010009T3 (en) 2006-04-21 2017-10-02 Senomyx Inc PROCEDURES FOR THE PREPARATION OF SOLID FLAVOR COMPOSITIONS
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
US7985753B2 (en) 2006-08-04 2011-07-26 Merz Pharma Gmbh & Co. Kgaa Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators
EP2091944B1 (fr) 2006-11-17 2011-05-18 Pfizer Inc. Composés bicyclocarboxyamides substitués
HRP20170027T1 (hr) 2006-11-22 2017-03-10 Clinical Research Associates, Llc Postupci liječenja downovog sindroma, sindroma lomljivog kromosoma x i autizma
MX2009010059A (es) 2007-03-22 2009-10-12 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
ES2369866T3 (es) 2007-04-19 2011-12-07 F. Hoffmann-La Roche Ag Derivados de dihidro-benzo[b][1,4]diazepin-2-ona-sulfonamida.
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
CN101348461B (zh) * 2007-07-17 2011-10-05 西安利君制药有限责任公司 用于老年痴呆症治疗的n-(3-吡啶甲酰氧基)-3,5-二甲基-1-金刚烷胺或其可药用盐
EP2064959B1 (fr) 2007-10-31 2012-07-25 Symrise AG Néomenthylamides aromatiques en tant qu'agents aromatisants
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
US8211882B2 (en) * 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
EP2401275B1 (fr) 2009-02-24 2013-07-24 Respiratorius AB Dérivés de naphthyridine à activité bronchodilatatoire
EP2544688B1 (fr) 2010-03-02 2016-09-07 President and Fellows of Harvard College Procédés et compositions pour le traitement du syndrome d'angelman
WO2011150380A1 (fr) 2010-05-28 2011-12-01 Xenoport, Inc. Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et des troubles associés
WO2012006760A1 (fr) * 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Composés tricycliques comme modulateurs allostériques des récepteurs métabotropes au glutamate
WO2012009646A1 (fr) 2010-07-15 2012-01-19 Xenoport, Inc. Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et de troubles associés
JP5837609B2 (ja) * 2010-11-30 2015-12-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ピリミジン誘導体
KR102529578B1 (ko) * 2014-08-29 2023-05-09 (주)아모레퍼시픽 신규 아다만탄 유도체 화합물
CN114539170B (zh) * 2021-12-31 2023-05-16 华南农业大学 一种用于同时检测金刚烷胺、喹乙醇、氯霉素的半抗原、人工抗原及其制备方法和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2050074A1 (de) * 1969-10-27 1971-05-06 E R Squibb & Sons Ine , New York, NY (V St A.) 4 (Adamantylaminoalkylamino) chinoline, deren Salze und Derivate, sowie Verfahren zu ihrer Herstellung und ihre Verwendung
US3632581A (en) * 1968-10-08 1972-01-04 American Home Prod Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products
DE2728248A1 (de) * 1976-06-24 1978-01-05 Debat Lab Nitroxolinderivate
EP0002066A1 (fr) * 1977-11-22 1979-05-30 Teva Pharmaceutical Industries Limited Adamantyl-2 hydrazines et compositions pharmaceutiques les contenant
EP0407192A2 (fr) * 1989-07-07 1991-01-09 Meiji Seika Kabushiki Kaisha Dérivés acyloxy-4-quinoléine et compositions insecticides et acaricides les contenant
JPH07179371A (ja) * 1993-12-21 1995-07-18 Canon Inc 液晶性化合物、それを含む液晶組成物、それを用いた液晶素子、それらを用いた表示方法、及び表示装置
WO1996005818A1 (fr) * 1994-08-19 1996-02-29 Nps Pharmaceuticals, Inc. Procedes et composes actifs au niveau des recepteurs de glutamate metabotropiques, destines au traitement d'affections et de troubles neurologiques
WO1996040641A1 (fr) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Derives de sulfonamides servant a moduler l'adherence cellulaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2509728A1 (fr) * 1981-07-17 1983-01-21 Roussel Uclaf Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
ES2112272T3 (es) * 1990-03-28 1998-04-01 Otsuka Pharma Co Ltd Derivado de quinolina, medicamento anti-ulceroso que contiene este derivado y produccion de este derivado.
JPH0441425A (ja) * 1990-06-07 1992-02-12 Tanabe Seiyaku Co Ltd ５―リポキシゲナーゼ阻害剤
JP2718830B2 (ja) * 1992-07-10 1998-02-25 ラボラトワール、グラクソ、ソシエテ、アノニム アニリド誘導体
CA2191980A1 (fr) * 1994-07-04 1996-01-18 Takashi Sohda Composes d'acide phosphonique, leur production et utilisation
WO1998050364A1 (fr) * 1997-05-03 1998-11-12 Smithkline Beecham Plc Derives de tetrahydroisoquinoline comme modulateurs des recepteurs d3 de la dopamine

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3632581A (en) * 1968-10-08 1972-01-04 American Home Prod Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products
DE2050074A1 (de) * 1969-10-27 1971-05-06 E R Squibb & Sons Ine , New York, NY (V St A.) 4 (Adamantylaminoalkylamino) chinoline, deren Salze und Derivate, sowie Verfahren zu ihrer Herstellung und ihre Verwendung
DE2728248A1 (de) * 1976-06-24 1978-01-05 Debat Lab Nitroxolinderivate
EP0002066A1 (fr) * 1977-11-22 1979-05-30 Teva Pharmaceutical Industries Limited Adamantyl-2 hydrazines et compositions pharmaceutiques les contenant
EP0407192A2 (fr) * 1989-07-07 1991-01-09 Meiji Seika Kabushiki Kaisha Dérivés acyloxy-4-quinoléine et compositions insecticides et acaricides les contenant
JPH07179371A (ja) * 1993-12-21 1995-07-18 Canon Inc 液晶性化合物、それを含む液晶組成物、それを用いた液晶素子、それらを用いた表示方法、及び表示装置
WO1996005818A1 (fr) * 1994-08-19 1996-02-29 Nps Pharmaceuticals, Inc. Procedes et composes actifs au niveau des recepteurs de glutamate metabotropiques, destines au traitement d'affections et de troubles neurologiques
WO1996040641A1 (fr) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. Derives de sulfonamides servant a moduler l'adherence cellulaire

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
B. PRAGER ET AL.: "Beilsteins Handbuch der Organischen Chemie, 12. Bd.", 1929, VERLAG VON JULIUS SPRINGER, BERLIN, XP002101991 *
B. PRAGER ET AL.: "Beilsteins Handbuch der Organischen Chemie, 9. Bd.", 1926, VERLAG VON JULIUS SPRINGER, BERLIN, XP002101990 *
CHEMICAL ABSTRACTS, vol. 115, no. 7, 19 August 1991, Columbus, Ohio, US; abstract no. 70978a, N. S. KOZLOV ET AL.: "Synthesis of adamantane-type beta-amino ketones" page 733; XP002101994 *
F. HONG ET AL.: "Design, synthesis and pharmacological test of a quinoline based, nonpeptidic analogue of neurotensin(8-13)", J. CHEM. SOC., PERKIN TRANS. 1, vol. 14, 1997, pages 2083 - 2088, XP002101983 *
F. SZTARICSKAI ET AL.: "Synthese und virushemmende in-vitro-Wirkung neuerer 1-substituierter Adamantanderivate", PHARMAZIE, vol. 30, no. 9, 1975, pages 571 - 581, XP002101986 *
G. FENECH ET AL.: "Derivati amidici dell'acido 1-adamantancarbossilico a potenziale attivita antivirale ed antitumorale", BOLL. CHIM. FARM., vol. 118, no. 2, 1979, pages 78 - 87, XP002101981 *
H. ZIMMER, H. D. BENSON: "Kondensierte Imidazole; Versuche zur Synthese des 13,16- und 14,16-Diazasterin-Gerüstes", CHIMIA, vol. 26, no. 3, 1972, pages 131 - 133, XP002101985 *
H.-G. BOIT: "Beilsteins Handbuch der Organischen Chemie", 1970, SPRINGER-VERLAG, BERLIN, XP002101992 *
K. H. KIM ET AL.: "Quantitative Structure-Activity Relationship in 1-Aryl-2-(alkylamino)ethanol Antimalarials", J. MED. CHEM., vol. 22, no. 4, 1979, pages 366 - 391, XP002101988 *
L. C. MARCH ET AL.: "Antimalarials. 2. Dihydro-1,3-oxazinoquinolines and Dihydro-1,3-pyridobenzoxazines", J. MED. CHEM., vol. 16, no. 4, 1973, pages 337 - 342, XP002101989 *
M. ZANISI ET AL.: "Excitatory amino acids as modulators of gonadotropin secretion", AMINO ACIDS, vol. 6, no. 1, 1994, pages 47 - 56, XP002101984 *
N. G. KOZLOV, G. P. KOROTISHOVA: "Synthesis of 1-(1-adamantyl)-2,3-dihydroxy-3-R-1-propanones", ZH. OBSHCH. KHIM., vol. 66, no. 12, 1996, pages 2039 - 2041, XP002101987 *
PATENT ABSTRACTS OF JAPAN vol. 095, no. 010 30 November 1995 (1995-11-30) *
R. LUCKENBACH: "Beilsteins Handbuch der Organischen Chemie, 3. u. 4. Eg., 22. Bd.", 1979, SPRINGER-VERLAG, BERLIN, XP002101993 *
S. S. SABRI ET AL.: "Syntheses and Antibacterial Activity of Some New N-(3-Methyl-2-quinoxalyl) Amino Alcohols and Amine 1,4-Dioxides", J. CHEM. ENG. DATA, vol. 29, no. 2, 1984, pages 229 - 231, XP002101982 *
VESTSI AKAD. NAVUK BSSR, SER. KHIM. NAVUK, no. 1, 1991, pages 60 - 65 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895050B2 (en) 2003-08-06 2014-11-25 Senomyx, Inc. Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof

Also Published As

Publication number Publication date
IL136250A (en) 2006-12-10
NZ505207A (en) 2003-10-31
JP2001524468A (ja) 2001-12-04
CN1554649A (zh) 2004-12-15
AU771358B2 (en) 2004-03-18
AU2004202776A2 (en) 2004-07-22
CN1285820A (zh) 2001-02-28
CN1158264C (zh) 2004-07-21
MXPA00004940A (es) 2002-10-17
AU1531799A (en) 1999-06-15
EP1037878A2 (fr) 2000-09-27
WO1999026927A2 (fr) 1999-06-03
CA2311131A1 (fr) 1999-06-03
AU2004202776B2 (en) 2008-06-19
AU2004202776A1 (en) 2004-07-22
IL136250A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
WO1999026927A3 (fr) Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central
EP1595871A3 (fr) Antagonistes du recepteur metabotrope duglutamate et leur utilisation pour le traitement des maladies du systeme nerveux central.
EP1679313A3 (fr) Composés hétéropolycycliques et leur utilisation comme antagonistes du récepteur glutamate métabotropique
MY131442A (en) Excitatory amino acid receptor antagonists
WO1996019458A3 (fr) Composes modulateurs des recepteurs des steroides et procedes d'utilisation
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
EP0686629A3 (fr) Antagonistes des récepteurs de tachycinine cyclohexyliques
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
BG106762A (en) Polycycloalkylpurines as adenosine receptor antagonists
WO2001010846A3 (fr) Nouveaux composes de 1,4-benzodiazepine et derives de ces derniers
HUP0002031A3 (en) Use of benzotiophen derivatives for production pharmaceutical compositions having activity against central nervous system disorders
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
FI945807A0 (fi) 2,5-diokso-2,5-dihydro-1H-bents/b/atsepiinit NMDA-reseptorin antagonisteina
WO1996023769A3 (fr) Composes heterocycliques possedant une activite antagoniste vis-a-vis du recepteur de 5ht¿2c?
WO1999029308A3 (fr) Procede pour lutter contre l'obesite
GR3034354T3 (en) IMIDAZO 1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
WO2004048318A8 (fr) Procede ameliore pour la preparation d'indenes 1,3-substitutees
PL335501A1 (en) Quinoxalinodiones
HK1031226A (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 136250

Country of ref document: IL

Ref document number: 98813148.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2311131

Country of ref document: CA

Ref document number: 2311131

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/004940

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref document number: 2000 522085

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15317/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 505207

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1998959535

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998959535

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 15317/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 178023

Country of ref document: IL